Which Cell Therapy for Which Condition? 2026 Guide
Which cell therapy for which condition depends on the diagnosis, the dominant biological mechanism, the available evidence, and the regulatory pathway in your jurisdiction. In most cases, MSCs and exosomes fit signaling or immunomodulatory questions, while NK cells fit oncology-focused immune targeting. This guide gives clinicians, procurement teams, and informed patients a practical framework.
It focuses on brain, cancer, and hair indications because each one follows a different selection logic. For broader brand context, readers can review the Regenex Asia overview. The guide does not promote a one-size-fits-all answer. Instead, it shows where MSCs, NK cells, or exosomes may fit, where evidence still evolves, and what teams should verify before they make a clinical decision.
Contents
Who This Routing Guide Helps
This guide helps beginner, intermediate, and advanced readers who want to match a therapy category to a clinical problem. It does not discuss cell therapy in the abstract. Instead, it answers a practical question: which cell therapy for which condition?
For example, a clinician may need a shortlist for a patient population. A clinic may assess which modality fits its workflow and compliance obligations. Meanwhile, an informed patient may want to know why one therapy comes up instead of another. You will get a condition-based framework for deciding when MSCs, NK cells, or exosomes are biologically plausible, how mature the evidence base appears, and where regulatory caution matters across Asia-Pacific practice settings.
What You Will Learn
How to Think About Which Cell Therapy for Which Condition
Start with mechanism, not marketing category
Clinicians usually consider MSC therapies when the treatment goal centers on immunomodulation, trophic support, and tissue-repair signaling. By contrast, exosomes are acellular signaling products that may deliver some paracrine effects associated with parent cells. However, standardization, potency testing, and indication-level evidence still vary. NK cell therapy belongs to a different clinical family. Its main rationale is direct immune surveillance and cytotoxic targeting. As a result, it fits oncology and some investigational infectious disease settings far better than hair or degenerative brain presentations.
Match the condition to the dominant biological problem
If the problem is degenerative or inflammatory tissue dysfunction, MSCs or exosomes may enter the conversation. If the problem is malignant cell burden, NK cells may align more closely. Therefore, “stem cell vs exosome vs NK cell” only becomes useful after the diagnosis is clear. Research indexed on PubMed and registered studies on ClinicalTrials.gov show very different trial landscapes for neurodegeneration, blood cancers, and alopecia.
Separate investigational use from established care
Most applications discussed in private regenerative medicine markets do not equal standard-of-care therapies. Regulatory standing can differ sharply by country. In Asia-Pacific settings, oversight may involve Singapore HSA, Japan PMDA, Australia TGA, Thailand FDA, South Korea MFDS, or India CDSCO. For Malaysia-related communications, teams need extra caution because many disease-treatment advertising claims to the public are restricted, and non-hematopoietic stem cell uses may remain investigational.
Use category resources only after the clinical route is clear
Readers comparing general cell therapy pathways may also want a broader look at Regenerative Cell Therapy and the more focused cross-hub review of MSC vs NK vs exosome. You can also review Regenex Products: Stem Cells, NK Cells and Exosomes — Complete Overview for a product-level summary. Those resources help once the first routing question is clear: which cell therapy for which condition, and what mechanism is actually relevant?
Exosomes in Practice: Which Cell Therapy for Which Condition and Why Standardization Matters
Exosomes are a subset of extracellular vesicles commonly described in the size range of roughly 30 to 150 nanometers. They are not living cells. Instead, they are membrane-bound packages released by cells that can carry biologically active cargo, including proteins, lipids, messenger RNA (mRNA), and microRNA. In clinical terms, this matters because the proposed mechanism is cell-to-cell communication and pathway modulation, not engraftment or long-term persistence of administered cells.
“MSC-derived exosomes” refers to exosomes harvested from mesenchymal stromal cell cultures under controlled conditions. This differs from exosomes derived from other cell sources. It also differs from products marketed loosely as “stem cell exosomes” without clear source documentation. In clinic settings, source matters because the parent cell type, culture conditions, and manufacturing controls can influence the composition and functional profile of the vesicles. The phrase “cell-free” can help explain that live cells are not administered. However, teams should not read it as risk-free. The risk profile may differ from live-cell therapies, yet contamination risk, inconsistent payload, and unclear dose definition can still matter clinically.
How exosome dose and identity should be checked
Standardization is the recurring challenge for exosome-based approaches. Unlike conventional pharmaceuticals, where a stable molecular structure defines the active ingredient, exosome products are complex biologics. As a result, “what is in the vial” can vary. Dose definition is a clear example. Some suppliers describe dose by particle count, some by protein content, and some by volume. Those metrics are not automatically interchangeable.
A clinic making a defensible decision should expect a clear rationale for how dose is defined, how it is measured, and how that definition relates to a proposed clinical effect in the target indication. This point matters when readers ask which cell therapy for which condition, because exosome quality can change the answer.
Quality controls clinics should verify
For procurement and governance teams, exosome due diligence should function as a quality-system exercise, not a branding exercise. Source documentation should be available, including donor eligibility where applicable, traceability, and confirmation of the cell source and culture system. In addition, the isolation and purification method should be disclosed because different approaches can yield different purity profiles and co-isolate non-exosomal material.
Identity characterization also matters. A program should document evidence that the product contains vesicles consistent with exosome-enriched fractions and that key markers and particle sizing methods are recorded. Potency assays remain a frequent market gap. Even so, they are central to showing functional activity relevant to the intended mechanism, even while the field still converges on best-in-class standards.
Release testing and logistics matter just as much. Sterility, endotoxin, and mycoplasma testing should be documented, and storage requirements should be explicit. Cold-chain integrity can affect biologic stability, so clinics should confirm shipping conditions, storage temperature, thawing instructions if applicable, and expiry criteria supported by stability data. Batch-to-batch consistency should not be assumed. A credible program typically expects lot-specific certificates, defined acceptance criteria, and a process for investigating deviations. Ultimately, exosome quality is not defined by the word “exosome” alone. It is defined by source transparency, manufacturing discipline, functional characterization, and jurisdiction-appropriate compliance.
Which Cell Therapy for Which Condition in Brain Care: MSCs or Exosomes?
In brain-related regenerative discussions, MSCs and exosomes are compared far more often than NK cells. The reason is mechanistic. Neurodegenerative and neuroinflammatory conditions are usually explored through immune modulation, support for damaged neural environments, and paracrine signaling. MSCs may enter the discussion because they can secrete cytokines, growth factors, and immunoregulatory mediators that could influence the injury environment. Exosomes are studied for their signaling cargo and theoretical ability to participate in cell-to-cell communication without transferring whole living cells.
Current research suggests biologic plausibility in several neurological contexts, but indication-level certainty remains limited for many applications. Reviews in the stem cell literature and early-phase studies suggest that safety and feasibility may be encouraging in selected settings. However, durable efficacy, ideal dosing, route of administration, and patient selection remain active questions. That is why this route usually starts with one question: which cell therapy for which condition if the goal is inflammatory modulation or trophic support? If that is the goal, MSCs or exosomes may be the relevant categories to compare.
NK cells are not the usual first-route option for neurodegeneration because their primary rationale is antitumor or antiviral immune activity rather than tissue repair signaling. Therefore, a clinic or patient comparing these three options for a degenerative brain presentation would usually narrow the field to MSCs versus exosomes first. For a deeper guide on which cell therapy for which condition in neurology, see the brain cell therapy guide and the patient-facing overview on MSC Therapy in Malaysia: Clinics, Protocols and the Regenex Advantage.
Which Cell Therapy for Which Condition in Cancer Care: NK Cells First
Cancer is the category where NK cells become the most clinically relevant of the three options discussed here. NK cells are part of innate immune defense and are being studied or used in certain settings because they may recognize and kill abnormal cells without the same antigen restriction as some adaptive immune strategies. In hematologic malignancies, NK-based approaches are often compared with other immunotherapies rather than with MSCs or exosomes.
MSCs are not typically selected as anticancer effectors in standard routing logic. In some research settings, teams may explore them as delivery vehicles or immune modulators, but that is not the same as choosing them as a primary antitumor strategy. Exosomes are also being studied in oncology, including as biomarkers and delivery systems, but this remains distinct from established cancer treatment pathways. For many real-world oncology evaluations, the practical comparison is more likely NK cells versus CAR-T, especially in blood cancer contexts. Readers can review the dedicated cancer cell therapy guide and relevant category context for CAR-T Cell Therapy.
Public-facing content about cancer requires particular care in Malaysia and other regulated markets because advertising restrictions may prohibit treatment claims for certain diseases, including cancer. Therefore, any patient or clinic assessment should stay anchored to oncologist oversight, formal eligibility criteria, manufacturing quality controls, adverse-event monitoring, and jurisdiction-specific approvals. For oncology routing, NK cells may be the most biologically aligned option of the three, but that does not mean universal suitability or broad regulatory availability. Readers who need local context can also review NK Cell Therapy in Malaysia: Providers, Protocols and Regenex NK Cells.
Which Cell Therapy for Which Condition in Hair Loss: MSCs or Exosomes?
Hair restoration is another area where MSCs and exosomes are compared far more often than NK cells. The biological question in alopecia is not tumor cell killing. Instead, it involves follicular signaling, inflammatory balance, and support for the scalp microenvironment. Research suggests that mesenchymal stromal cells and their secreted vesicles may influence pathways related to follicle cycling, angiogenesis, and tissue signaling. That makes MSCs and exosomes the more relevant comparator set.
Even here, the evidence base needs careful interpretation. Hair loss is not a single diagnosis. Androgenetic alopecia, alopecia areata, scarring alopecias, endocrine causes, and nutritional or medication-related shedding differ significantly in mechanism. As a result, a patient with autoimmune alopecia may not be evaluated the same way as a patient with patterned hair loss. Sources such as MedlinePlus Hair Loss and the American Academy of Dermatology Hair Loss Center are useful for baseline diagnostic framing, but treatment selection still depends on specialist evaluation.
NK cells are generally not routed to hair loss evaluation because the mechanism does not fit the problem being treated. So when a clinician or patient asks which cell therapy for which condition in hair care, “MSC or exosome for hair?” is at least the right biologic starting point. The next step is to confirm diagnosis, assess product quality, and review the depth of clinical evidence. For a more focused treatment discussion, see the hair loss guide and the category page for Exosome Therapy.
Where PRP Fits in the Routing Conversation (and Why Readers Ask “PRP vs Stem Cell”)
Many readers who start by comparing “MSC vs exosome” for hair or skin quickly encounter the adjacent question: “PRP vs stem cell.” PRP, or platelet-rich plasma, is a different biologic category. It is an autologous blood-derived concentrate that aims to deliver a higher concentration of platelets and platelet-associated growth factors to a target tissue. It is not a cell therapy in the same sense as MSCs or immune effector cells, and it is not an extracellular vesicle product like exosomes.
PRP tends to be discussed because many clinics already know the workflow, it can be performed using the patient’s own blood, and its regulatory handling in many jurisdictions is often clearer than therapies that involve allogeneic cells or manufactured biologic products. In hair and aesthetic contexts, PRP also has a more established clinical footprint than many exosome offerings marketed for similar goals, although results may vary by diagnosis, patient factors, and protocol choices. The practical point is not that PRP is “better.” Rather, its category characteristics are different, and those differences affect routing.
As a general routing concept, PRP may be considered earlier in milder presentations, as an adjunct to established dermatologic care, or when a clinician prioritizes autologous approaches with simpler sourcing requirements. MSC or exosome discussions may enter later for selected patients where a clinic is evaluating investigational biologics with a signaling or immunomodulatory rationale, and where product characterization and governance can be documented to a defensible standard. Importantly, patients considering any of these options should be evaluated by a qualified medical professional, because the correct starting point remains diagnosis confirmation and an evidence-informed discussion of expected variability and potential risks.
Which Cell Therapy for Which Condition: Comparison at a Glance
| Therapy category | Main mechanism described in this guide | Conditions most often discussed in this guide | Key note |
|---|---|---|---|
| MSC therapy | Immunomodulation, trophic support, and regenerative signaling | Brain, hair, orthopedic, neurological, and some aesthetic contexts | Evidence varies by indication, and many uses remain investigational outside established hematopoietic stem cell transplantation frameworks. |
| NK cell therapy | Direct immune surveillance and cytotoxic targeting | Blood cancers and some investigational viral applications | Usually requires stronger oncology governance, immune compatibility review, and release criteria. |
| Exosome-based approaches | Cell-free signaling and paracrine-biologic effects | Brain, hair, and some aesthetic contexts | Standardization, source characterization, potency, and purification remain major decision points. |
MSC therapy
MSC therapy aligns best with conditions where immunomodulation, stromal support, or regenerative signaling are central to the treatment concept. It is commonly discussed in orthopedic, neurological, and some aesthetic or hair-related contexts. Evidence varies by indication, and many uses remain investigational outside established hematopoietic stem cell transplantation frameworks. For readers assessing adjacent indications, the osteoarthritis guide is a useful example of how indication fit changes the evaluation.
NK cell therapy
NK cell therapy is most relevant where immune-mediated targeting of abnormal or infected cells is the objective. That generally points toward blood cancers and some investigational viral applications rather than degenerative or aesthetic use. The treatment pathway usually requires stronger attention to immune compatibility, release criteria, administration setting, and oncology governance. For infectious disease context, readers can review the viral infections guide.
Exosome-based approaches
Exosome-based approaches are typically considered where cell-free signaling is preferred or where clinics and patients are exploring paracrine-biologic concepts without live-cell administration. The appeal is practical. However, the key challenge is standardization. Exosome source characterization, potency, purification, and release testing may vary significantly between providers. Evidence is often earlier-stage than marketing language suggests, especially outside narrow research contexts. This is relevant not only to hair indications but also to aesthetic use cases such as those covered in the skin aging guide.
How Clinics and Patients Should Make the Final Choice
1. Define the indication precisely
“Brain,” “cancer,” and “hair loss” are umbrella terms. The actual diagnosis determines whether a therapy category is even biologically relevant.
2. Check whether the mechanism matches the problem
MSC and exosome logic centers on signaling and modulation. NK cell logic centers on immune cytotoxicity. A mismatch here should stop the evaluation early.
3. Review the evidence by indication, not by product class alone
A therapy category may have plausible science overall but weak clinical support for the exact condition under review. Literature quality, phase of study, comparator arms, and safety monitoring all matter.
4. Verify regulatory and manufacturing status
Clinics should ask about donor screening, traceability, sterility testing, identity and potency characterization, storage controls, and documentation. Regulatory expectations differ across HSA, PMDA, TGA, Thailand FDA, MFDS, and CDSCO frameworks, but quality-system discipline remains central across jurisdictions.
5. Distinguish advisory content from individualized medical judgment
Even a strong product-category fit does not decide eligibility. Comorbidities, concurrent therapies, cancer status, autoimmune activity, pregnancy status, and prior treatment history may all affect suitability.
Regenexasia presents itself as a regional educational resource for clinically oriented cell therapy evaluation. If you are mapping options for a clinic program or trying to understand which cell therapy for which condition, the most productive next step is usually a documented clinical review rather than a marketing-driven comparison. Readers can also review ── REGENERATIVE CELL THERAPY ── to compare broader biologic categories before discussing sourcing, protocol design, or treatment candidacy with a qualified medical team.
Candidate Fit and Contraindications: Which Cell Therapy for Which Condition Also Depends on Eligibility
“Who is not a candidate?” is one of the most important questions in cell therapy decision-making. Teams should ask it before a patient or clinic commits to a product category. Screening logic is condition-agnostic at the first pass. If a patient has an uncontrolled infection, unstable cardiopulmonary status, decompensated organ disease, or another acute medical instability, clinicians generally defer elective biologic interventions until they address the underlying risk. Pregnancy and breastfeeding also trigger added caution because many regenerative applications lack adequate evidence for maternal and fetal safety. In addition, regulatory frameworks often require a higher threshold for risk exposure in these populations.
Baseline exclusions and medical stability
Active malignancy is another area where routing requires discipline. In non-oncology regenerative indications, a patient with an active cancer diagnosis, recent cancer treatment, or unresolved oncologic surveillance questions typically needs oncology input before any immunomodulatory or biologic therapy is considered. The reason is not that every biologic approach is contraindicated in every cancer context. Rather, risk assessment, monitoring, and governance must match the clinical stakes. Severe immune dysregulation and uncontrolled autoimmune activity can also complicate eligibility because baseline inflammation, immunosuppressive regimens, and infection risk may alter the expected risk-benefit balance.
Modality-specific risks and procedure factors
Contraindications can also be modality-dependent. Immune effector cell therapies, including NK-cell based approaches and other engineered immune modalities, sit closer to oncology-grade governance. They may require more intensive eligibility criteria, clearer adverse-event readiness, and tighter monitoring protocols. MSC and exosome approaches are often discussed through immunomodulatory and signaling mechanisms, but they still require careful screening, especially in patients with complex comorbidities or concurrent immunosuppressive therapies. Procedure-related considerations also matter. If delivery involves an injection or an invasive step, anticoagulation status, bleeding risk, and medication reconciliation may directly influence whether the procedure is safe to perform.
Clinics building a responsible program typically document baseline status in a way that matches the indication. That may include relevant labs, imaging, and functional assessments, plus a structured medication review and an adverse event plan that covers monitoring, escalation pathways, and follow-up. Informed consent should reflect whether the application is investigational in the local jurisdiction, what is known about safety and uncertainty, and what realistic goals look like for the patient’s specific diagnosis. Ultimately, which cell therapy for which condition is only one part of the decision. Patients should treat this as a clinical conversation, not a marketing decision, and consult a qualified medical professional before pursuing any cell-based or exosome-based intervention.
Common Selection Mistakes
Next Steps and Condition-Specific Reading
If your question is mainly about route selection for one condition family, the most efficient next step is to read the dedicated guide for that area rather than continue comparing all three modalities at once. For neurodegenerative presentations, start with the brain guide. For hematologic oncology questions, move to the cancer guide. For alopecia and scalp-focused treatment decisions, use the hair guide first. Readers exploring adjacent regenerative applications may also find value in the osteoarthritis, skin aging, and viral infection resources linked throughout this page. This sequence usually produces better decisions because it narrows the biology, evidence, and compliance questions before therapy procurement or patient consent discussions begin.
Clinical Considerations for Which Cell Therapy for Which Condition
Across brain, cancer, and hair use cases, the evidence base is not equally mature. Research indexed through PubMed and registered on ClinicalTrials.gov suggests that NK cell therapy has a clearer conceptual fit in oncology, while MSCs and exosomes are more often studied for tissue signaling, inflammatory modulation, and regenerative support. Yet mechanistic fit is only the first filter. Clinical-grade assessment also requires attention to product characterization, route of administration, dosing rationale, adverse-event surveillance, and jurisdiction-specific compliance. Regulatory bodies such as Singapore HSA, Japan PMDA, Australia TGA, Thailand FDA, South Korea MFDS, and India CDSCO may apply different pathways, but all place weight on safety, manufacturing discipline, and truthful indication framing. In Malaysia, special care is required because many non-HSCT stem cell uses may be investigational and public disease-treatment advertising may be restricted. Therefore, clinics should evaluate whether the intended indication is supported by defensible clinical data and whether product governance is adequate for the level of risk involved.
Strengths and Considerations
Strengths
Considerations
Frequently Asked Questions
Is there a single best choice for which cell therapy for which condition?
No. The appropriate route depends on diagnosis, biological mechanism, evidence level, and regulatory setting. NK cells, MSCs, and exosomes are not interchangeable categories. A therapy that may be rational in blood cancer would not typically be the first comparison set for alopecia or neurodegeneration.
How do I know whether MSCs or exosomes make more sense for brain-related evaluation?
The first question is whether the treatment goal is immunomodulation and trophic support rather than direct immune cell killing. If that is the case, MSCs and exosomes may be the more relevant comparison. After that, product characterization, administration route, and indication-specific evidence should be reviewed carefully.
Why are NK cells more often discussed for cancer than for hair loss or neurodegeneration?
NK cells are immune effector cells with antitumor and antiviral relevance. Hair loss and degenerative brain disorders are usually not framed around direct cytotoxic targeting of abnormal cells. That is why NK cell therapy generally enters oncology and some infectious disease discussions before regenerative or aesthetic ones.
Are exosomes just a simpler version of stem cell therapy?
No. Exosomes are acellular extracellular vesicles, while MSC therapies involve living cells with broader biologic behaviors. Some proposed benefits may overlap at the signaling level, but the products are not clinically identical. Safety assessment, potency testing, and evidence interpretation should treat them as separate categories.
Who is not a candidate for stem cell therapy?
Eligibility depends on diagnosis, modality, and individual risk profile, but common reasons to defer or avoid elective regenerative cell-based interventions include uncontrolled infection, unstable comorbidities, pregnancy or breastfeeding, and situations where the patient’s goals are not realistic for the evidence available. Active malignancy or unresolved cancer surveillance questions generally require oncology input before considering immunomodulatory biologics for non-oncology purposes. Procedure-related issues such as anticoagulation and bleeding risk can also matter when administration involves an injection or other invasive step. A qualified healthcare professional should review candidacy and informed consent before any treatment decision.
What diseases can cell therapy treat?
Cell therapy is an umbrella term that includes very different modalities. Some cell therapies are established as standard care in specific settings, such as hematopoietic stem cell transplantation for certain blood disorders, and approved immune-cell therapies for select cancers in certain jurisdictions. Many other applications discussed in regenerative medicine, including non-hematopoietic MSC and exosome uses for degenerative, neurologic, or aesthetic indications, may be investigational and vary by country and regulator. The responsible question is not only “what can it treat,” but also “what is supported by indication-specific evidence and permitted within the local regulatory pathway.”
Will insurance pay for T cell therapy?
Coverage depends on the country, insurer, and the specific therapy and indication. In jurisdictions where certain T cell therapies are approved for defined cancer indications, reimbursement may be available through national health systems or insurance plans, but eligibility criteria can be strict and out-of-pocket costs may still apply. For investigational use, off-label use, or treatment delivered outside recognized coverage frameworks, insurance may not reimburse. Patients should confirm coverage details directly with their insurer and treating oncology team before proceeding.
Which is better, PRP or stem cell therapy?
They are not interchangeable categories. PRP is an autologous blood-derived product commonly used in orthopedic, dermatologic, and hair contexts, with outcomes that can vary by diagnosis and protocol. “stem cell therapy” can refer to a range of approaches, including MSC-based interventions that are often discussed for signaling and immunomodulatory goals, and many such uses may be investigational depending on the jurisdiction. The better question is which option fits the diagnosis, risk tolerance, evidence quality, and regulatory setting, which should be reviewed with a qualified medical professional.
Can patients choose the therapy themselves after reading online guides?
Online guides can support informed questions, but they should not replace medical assessment. Diagnosis confirmation, contraindications, prior treatment history, and regulatory access all require review by a qualified healthcare professional. This is especially important for oncology, neurologic disease, and autoimmune hair loss.
What should a clinic verify before adopting a cell therapy line?
Clinics should verify sourcing, donor eligibility, sterility controls, traceability, identity testing, storage and transport conditions, adverse-event protocols, and compliance documentation relevant to their jurisdiction. They should also confirm whether the intended indication is investigational, established, or restricted in public-facing communications.
Are these therapies approved everywhere in Asia?
No. Regulatory treatment varies across Asia-Pacific markets. A product category discussed in one country may face different approval, import, clinical trial, or advertising requirements in another. Reference to HSA, PMDA, TGA, Thailand FDA, MFDS, or CDSCO should be jurisdiction-specific rather than assumed to be transferable.
What is the main question for hair loss patients comparing MSCs and exosomes?
The main question is whether the hair loss diagnosis is appropriate for biologic signaling-based therapy and whether there is a credible rationale for the specific product being offered. Pattern hair loss, autoimmune alopecia, and scarring alopecias differ significantly, so treatment logic should not be generalized.
Where should someone start if they are still unsure which category fits?
Start with the condition-specific guide that matches the diagnosis family most closely. That usually produces a better decision path than comparing all therapy categories at once. If the diagnosis is still uncertain, medical workup should come before therapy selection.
Glossary
Key Takeaways
Conclusion
The most reliable way to decide which cell therapy for which condition is to route the decision through the condition first, then through mechanism, evidence quality, and regulatory fit. That approach often clarifies the field quickly. Brain and hair questions often narrow to MSCs versus exosomes. Cancer questions more often move toward NK cell or other oncology-specific immunotherapy evaluation. For clinics, this supports better program design and more defensible procurement decisions. For patients, it supports more focused discussions with the treating specialist. If you want a structured next step, review the condition-specific Regenex guides linked above and then consult a qualified medical professional or contact Regenexasia to discuss the available clinical information and the compliance considerations relevant to your region.
This article is intended for informational purposes only and does not constitute medical advice. Cell therapy treatments should only be pursued under the guidance of a qualified medical professional. Regulatory requirements for cell therapies vary by jurisdiction across Asia. Always consult the relevant regulatory authority and a licensed healthcare provider in your region before making any clinical or treatment decisions. Many non-hematopoietic stem cell, exosome, and immune-cell applications discussed in regenerative medicine may be investigational for specific indications. No outcome is guaranteed, and suitability should be assessed individually.
About the Author
Dr. Jay Gobi is a Kuala Lumpur-based Medical Doctor and clinical innovator supporting Regenex Asia's work in advanced cellular therapies. With frontline experience at Hospital Kuala Lumpur and a focus on evidence-based medicine, he helps bridge clinical practice, patient safety and biotherapeutic innovation across stem cell, NK cell and advanced immunotherapy applications.